New Trends,peptide-based LYTAC

The term "Tac peptide" encompasses a diverse range of molecules with significant implications in biological research, diagnostics, and therapeutic development. While the initial focus was on the Tac peptide of the IL-2 receptor, the term has evolved to include various peptide-based strategies for targeted protein degradation and drug delivery. This article delves into the different facets of Tac peptides, exploring their origins, applications, and the cutting-edge research shaping their future.

Understanding the Original Tac Peptide and its Context

The Tac peptide originally referred to a specific peptide component associated with the Interleukin 2 (IL-2) receptor. IL-2 is a critical cytokine for T-cell proliferation and immune regulation. Research in the late 1980s, such as studies by Edidin and colleagues, investigated the lateral diffusion of this Tac peptide within the plasma membrane, providing evidence for its association with other membrane components like the T27 peptide. Further work by Kato and others in 1987 focused on the structure of the Tac antigen, noting its ability to form disulfide-linked homodimers, a crucial aspect for its function in receptor signaling. Early diagnostic investigations also explored the presence of urinary Tac peptide as a potential biomarker, with elevated levels observed in certain hematological malignancies like adult T-cell leukemia, as reported by Marcon et al. in 1988. This highlights an early application of peptide analysis in disease detection.

The Rise of Peptide-Based Degradation Technologies: PROTACs and beyond

More recently, the term "TAC" has become intrinsically linked to advanced therapeutic strategies, particularly Proteolysis-targeting chimeras (PROTACs). PROTACs are bifunctional molecules designed to hijack the cell's natural protein degradation machinery, the ubiquitin-proteasome system, to eliminate disease-causing proteins. The fundamental principle involves a PROTAC molecule bridging a target protein with an E3 ubiquitin ligase, leading to the target protein's ubiquitination and subsequent degradation.

The field of PROTAC research and development has rapidly expanded, with a significant focus on peptide-based PROTACs. Compared to their small-molecule counterparts, peptide PROTACs offer several advantages, including enhanced biodegradability, lower toxicity, and greater flexibility in structural design, allowing for multitargeting capabilities. Research by Zhu et al. and Lu et al. published in 2025 and 2026, respectively, underscore the growing importance of peptide PROTACs as a powerful therapeutic strategy.

Beyond PROTACs, other peptide-based degradation technologies are emerging. LYTACs (Lysosome-Targeting Chimeras), for instance, utilize peptide-based LYTACs to deliver target proteins to lysosomes for degradation. IGF2 peptide-based LYTACs, as reported by the Li group in October 2023, demonstrate the potential for developing pure protein LYTACs from readily producible peptides. Similarly, the development of AUTOTACs (Autophagy-Targeting Chimeras) by Ji et al. in 2022 introduced a chemical biology platform for targeted protein degradation via autophagy.

Pep-TACs: A Novel Approach to Targeted Degradation

A specific and highly promising application of Tac peptides in targeted degradation is represented by Pep-TACs. These are covalent Pep-TACs that have demonstrated significant efficacy in degrading specific proteins. Xiao et al.'s research, with publications in 2025, highlights that covalent Pep-TACs can efficiently degrade the expression of PD-L1 on various immune cells, including tumor cells, dendritic cells, and macrophages. This ability to degrade PD-L1 is crucial for cancer immunotherapy, as it can block the PD-1/PD-L1 interaction, activate T-cell function, and enhance anti-tumor immune responses. Studies on Pep-TAC peptides have shown their ability to target cancer cell receptors like transferrin (TRFC) and programmed-death ligand 1 (PD-L1), leading to anti-tumor effects.

The development of peptide-based chimeric strategies for targeted degradation, as explored in research slated for December 2025, further emphasizes the versatility of Pep-TACs. These strategies aim to efficiently degrade PD-L1, block immune checkpoints, and ultimately boost anti-cancer immunity.

Other Applications and Emerging Trends

The versatility of peptides extends beyond degradation strategies. The TAT peptide, derived from the trans-activating transcriptional activator (Tat) of HIV-1, is a well-known cell-penetrating peptide that facilitates the entry of various molecules into cells. This property makes TAT peptide a valuable tool in drug delivery and gene therapy research.

In the realm of diagnostics and therapeutics, peptide conjugates are also gaining traction. The rs-TAC PDC, a peptide drug-conjugate, has shown promise in treating diabetic nephropathy, offering better therapeutic effects and fewer side effects than tacrolimus alone, as indicated by Gao et al. in 2024.

The exploration of